Industry
Featured experience
Novo Nordisk acquisition of certain Catalent sites from Novo Holdings
We are advising Novo Nordisk on the acquisition
AbbVie $15 billion senior notes offering
The investment-grade offering comprised seven tranches
Auna $360 million U.S. IPO
We advised Auna on its U.S. IPO and NYSE listing
Trial victory in patent infringement case for Magnolia Medical Technologies
We served as lead trial counsel for Magnolia Medical in an action against its sole competitor
FTC clearance of Novo Nordisk acquisition of certain Catalent sites
We secured regulatory approval following a lengthy review
Revolution Medicines $750 million stock and pre-funded warrants offering
The stock is listed on the Nasdaq Global Select Market
Cross Country Healthcare $615 million acquisition by Aya Healthcare
We are advising Cross Country Healthcare on the transaction
Laekna HK$236 million placement of shares
We advised Laekna on the placement of new shares
Alignment Healthcare $330 million convertible senior notes offering
The convertible notes are due 2029
ACELYRIN $150 million at-the-market offering
The shares are listed on the Nasdaq Global Select Market
Cardinal Health $2.9 billion notes offering
The investment-grade notes are due 2026, 2029, 2034 and 2054
Omnicell $172.5 million convertible senior notes offering
The convertible senior notes are due 2029
Horizon Mutual Holdings debut $600 million senior notes offering
The investment-grade notes are due 2034
GSK strategic alliance with Vesalius Therapeutics
We advised GSK on the transaction